Loading
Sepsis Treatment · Journal article
International Journal of Pharmaceutics: X · June 15, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study describing a multifunctional cerium dioxide nanoparticle platform coated with macrophage membranes and loaded with imipenem-cilastatin for sepsis treatment. The system was tested in vitro and in a mouse cecal ligation and puncture model, demonstrating reduced inflammatory cytokines, alleviated multi-organ injury, and enhanced survival, but the study lacks the clinical evidence, detailed quantitative outcomes, and comparative data required to establish clinical utility.
Preclinical in vitro and animal model study. Mice with cecal ligation and puncture-induced sepsis; macrophage cell cultures for in vitro assays. Intervention: IC@CeO₂@MM nanoplatform (cerium dioxide nanoparticles loaded with imipenem-cilastatin sodium hydrate and coated with macrophage membranes). China (multiple departments across China Medical University hospitals).
IC@CeO₂@MM effectively reduced both systemic and local inflammatory cytokines in CLP-induced mouse sepsis model The nanoplatform alleviated multi-organ injury in liver, kidneys, and intestines Enhanced survival rates were observed in treated animals
No specific quantitative survival rates, mortality reduction percentages, or confidence intervals reported No information on dosing, pharmacokinetics, biodistribution, or safety profile in vivo
This research presents a conceptual advance in multi-targeted sepsis therapy design but remains at the preclinical stage. Clinicians should not consider this for patient application; it requires extensive further development, including pharmacokinetic studies, toxicology, efficacy comparison with standard care, and eventual clinical trials before any therapeutic consideration.
This is an early-stage preclinical study demonstrating a novel nanoplatform in a mouse sepsis model with in vitro validation, lacking human clinical data and requiring confirmation in larger studies before clinical translation.
As stated by the source record.
This research presents a conceptual advance in multi-targeted sepsis therapy design but remains at the preclinical stage. Clinicians should not consider this for patient application; it requires extensive further development, including pharmacokinetic studies, toxicology, efficacy comparison with standard care, and eventual clinical trials before any therapeutic consideration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Sepsis is a life - threatening systemic inflammatory response syndrome triggered by pathogenic infections, which is characterized by severe oxidative stress, immune dysregulation, and multiple organ dysfunction, accompanied by a high mortality rate. Its primary pathogenesis encompasses pathogen - induced immune overactivation, resulting in cytokine storms, oxidative damage, tissue injury, and organ failure. This research developed a bionic nanotherapeutic system for the treatment of sepsis. Cerium dioxide (CeO₂) nanoparticles with inherent antioxidant activity were employed as carriers, loaded with the broad - spectrum antibiotic imipenem - cilastatin sodium hydrate (IC), and further coated with macrophage membranes (MM). The MM conferred immune evasion, homologous targeting, and lipopolysaccharide (LPS) - neutralizing capabilities to the nanosystem.This integrated platform combines CeO₂ - mediated reactive oxygen species (ROS) scavenging, antibiotic - induced bactericidal effects, and MM - mediated inflammatory regulation. In vitro investigations verified its potent ROS - scavenging, LPS - neutralizing, anti - inflammatory, and antibacterial activities. In a cecal ligation and puncture (CLP) - induced mouse sepsis model, IC@CeO₂@MM effectively reduced both systemic and local inflammatory cytokines, alleviated multi - organ injury in the liver, kidneys, and intestines, and enhanced survival rates. Mechanistically, it maintained mitochondrial membrane potential and decreased mitochondrial ROS (mtROS) accumulation in macrophages.This synergistic strategy simultaneously achieves antibacterial, antioxidant, and immunomodulatory effects, presenting a promising and novel approach for the comprehensive management of sepsis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.